Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Misery has company..
Or Peregrine?
It's always something.
It's alway diluted, and that's not sabotage. It's always miss handled, and that's not sabotage. It's always delayed, abandoned, discontinued, disappearing, and shelved, IMO, and that's not sabotage..
At some point maybe flipped PS just doesn't make ionic equation, and the proof is, as you said, there are no receptors... And no maintained electrostatic mechanism..
And What happens to flipped PS is repulsive Van der Waals force, IMO.
It's always something, but maybe you can't formulate an equation. Which means PS is scientifically insignificant?
It's always something..
All the best,
John
These receptor pockets are commonly known as endocytic pathways, FYI
Numerous PS receptor endocytic pathways have been shown to be hijacked as portholes to pathogenesis, including ZIKA propagation..
To say that PS has no binding reception is wrong and leaves me wondering how naive of knowledge on this subject many are..
However, knowledge has been interjected, with hopes of clarity and color..
All the best,
John
What happens to PS ionic net charge in a static necrotic environment?
Are pathogenic cells devoid of scramblase translocation? How long does PS survive, without an opposite ionic charge?
All the best,
John
Thanks CJ.. However, it sounds as though we may never accomplish designed "N" in Sunrise?
Per this quote,
"As Steve stated, we have already enrolled the number of patients required to achieve the trial’s main objectives, and expect to complete enrollment of the target sample size of 582 in the coming weeks"
This tells me that we are limping to the finish line, IMO.. Why?
All the best,
John
At risk of being ostracized, but is enrollment officially late and delayed?
Anyone concerned with peregrines inability to consummate this trial? I'm starting to wonder if there is a problem?
February 1st...
More credibility issues IMO..
All the best,
John
Welcome back Joe. Eom.
That's correct, and I failed to close the loop on my last post.
There were 4 basic principles in the sabatoging results.
Bavi + docetaxel
Bavi + placebo
Docetaxel + Placebo
Docetaxel alone
Resulted never before seen NSCLC astonishing stat sig phase II results..
All the best,
John
There were no real results in phase II
The sabatoging was successful in that way.
The 113% was not real and neither was the 60%, IMO.
However, it could be speculated this way, although it is just speculation, and non-confirmatory, and again sabatoge successful>> ask this question:
has a placebo ever been FDA approved, because in the case of Bavi's phase II, the 113% stat sig would have suggested as such.
Although the results were not considered REAL, the 113% did somehow happen.
In otherwords, the Placebo + Bavituximab results were astonishing, IMO.
All the best,
John
Greeting,
I'm looking to devesify my holdings and thought I would ask your opinion on what is the most undervalued alternative energy stock?
TIA,
All the best,
John
Wook,
Chemotherapy kills drug-sensitive cells, but leaves behind a higher proportion of drug-resistant cells.
There's your "one arm tied behind the back", for Bavituximab theory.
If it fails, don't ask how, because now you know.
If it succeeds, then it will be doing so in spite, and when added to other more synergistic therapeutics (Crestor), the sky will be the limit, IMO.
Your questions below will be answered as time permits.. Thanks.
You know I've been unable to put my finger on something that physiologically didn't add up with Bavi's MOA.
And honestly, Peregrine didn't know either, thus the change in understanding over the past 10 years or so.
The immunity, attachment, synergy with chemo's. The secondline, as opposed to first line treatment. It just didn't add up.
Especially the immunity, in conjunction with secondline chemo's. It just doesn't add up, IMO.
I've been working on a theory.
And there is a new MOA in town. One that is explainable, understandable, and provable.
All the best,
John
Wookie,
Bavi block PS. Statin eliminate pathway. Bavi bind PS. Immune cell recognize pathogenic cell. Statin initiate normal cell death. Bavi initiate immunity. Cancer go bye bye. Never come back.
Patient have no cancer, but also low cholesterol. Eat more fish and eggs, then forgive bad Statin for silly byproduct that starve cancer with help of Bavi friend and cancer immunity.
This All Big Fat Opinion.
All the best,
John
You guys are missing the boat and statins..
The point being that statin bio kinetics display antineoplastic properties. In other words, inhibitory, angiogenesis, cell division, metastasis, tumor growth, etc.. Statins also have proapoptotic properties.
I've explained how and it wasn't correctly digested.
Lastly, if you didn't know, cholesterol is a major structural component of cell membranes. More so than PS. And just like PS a cancer proliferator, albeit in a different way.
How you might ask?
Because, cancer cells use cholesterol biosynthetic pathways to proliferate. This is common knowledge, and scientifically accepted. At least in my world..
I'm so confident in this theory that I'd bet my life savings on combo Statin/Bavi besting Sunrise Chemo/Bavi results.
All the best,
John
In that case (spam away)! Everyone click on the donate link for MD!
Why didn't you tell us before? I mean the spam for a charitable cause?
All the best,
John
md,
Are your articles paid per click or read?
All the best,
John
I'm aware of plaques (betaamyloids) and alzheimers.
I'm also thinking on the cellular level, in regards to alternative statin MOA, especially in relation to AntiPS.
I believe you're relying on what you heard during the super bowl halftime commercial.. Can't help ya there..
Physiotherapeutically, Statins and AntiPS make for plausible science, IMO.
All the best,
John
Maybe to manipulate the market and bolster his short position, if Sunrise fails or is delayed??
All the best,
John
Thanks DJ,
It's just an opinion, and subject that I wnated some feedback on.. However, it seems most here would rather hear more pumpy talk..
Btw, if management were so confident in enrollment and completion, why would they authorize 375mm addional shares? Why not finish the trial, get regulatory approval and do a forward split? There's your additional 375mm shares..
All the best,
John
LOL..
I'm causing Peregrine to not be on schedule?? That's a good one!
I hope that would be tongue in check?
It doesn't take a genius to know that early completion is off the table. Or should we wait until December to call that one?
So, that leaves us with two possibilities, right on time, and a delay in enrollment.
That's realistic, logical discussion.
All the best,
John
As Nuke said, it would be more logical to know before hand.
I believe this would disqualify you from clinical study.
With that said, testing for a specific tumor biomarker is less than uniform. There are several different assays that could be used, however at the moment there is no specific consensus. Opdivo has an uphill battle in regards to educating these qualifications for treatment.
All the best,
John
Nuke,